Table 3

Secondary end points: (A) number of patients achieving the ACR20 response; (B) number of patients with improvement in the PASI score of ⩾50%

WeekPVAC (n = 18)Placebo (n = 18)p Value
(A)
12221.0
24320.6
12 and/or 24530.4
(B)
12551.0
24540.7
12 and/or 24850.3